TMPRSS2 and COVID-19: A recent study proposes three mechanisms by which nafamostat is effective against COVID-19: an anti-coronavirus action by inhibiting TMPRSS2, anti-disseminated intravascular coagulation (anti-DIC) by inhibiting the fibrinolysis responsible of the cytokine storm observed in the disease and antiplasmin action, which interferes with the known pathogenicity of plasmin cleaving the viral S protein [94].